Longitudinal Changes in Neuromelanin MRI Signal in Parkinson's Disease: A Progression Marker

摘要: Background Development of reliable and accurate imaging biomarkers dopaminergic cell neurodegeneration is necessary to facilitate therapeutic drug trials in Parkinson's disease (PD). Neuromelanin-sensitive MRI techniques have been effective detecting the substantia nigra pars compacta (SNpc). The objective current study was investigate longitudinal neuromelanin signal changes SNpc PD patients. Methods In this prospective, longitudinal, observational case-control study, we included 140 patients 64 healthy volunteers divided into 2 cohorts. Cohort I 99 early (disease duration, 1.5 ± 1.0 years) 41 analyzed at baseline (V1), where 79 32 were rescanned after 2.0 0.2 years follow-up (V2). II progressing 9.3 3.7 23 V1, 30 2.4 0.5 follow-up. Subjects scanned 3 T using 3-dimensional T1-weighted neuromelanin-sensitive imaging. Regions interest delineated manually calculate SN volumes, volumes corrected by total intracranial volume, signal-to-noise ratio, contrast-to-noise ratio. Results showed (1) significant reduction volume between visits, greater than nonsignificant volunteers; (2) no effects visit for intensity (signal-to-noise ratio); (3) interaction group visit; (4) female decrease increase ratio compared with male patients; (5) correlations severity duration. Conclusions We observed a progressive measurable neuromelanin-based PD, which might allow direct noninvasive assessment progression loss could represent target biomarker disease-modifying treatments. © 2021 Authors. Movement Disorders published Wiley Periodicals LLC on behalf International Parkinson Disorder Society.